{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:32:33Z","timestamp":1795066353617,"version":"4.10.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Center for Tumor diseases (NCT), Heidelberg","award":["HD02-NCTC-MAGELLAN"],"award-info":[{"award-number":["HD02-NCTC-MAGELLAN"]}]},{"DOI":"10.13039\/501100010441","name":"Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","award":["Physician Scientist-Programme"],"award-info":[{"award-number":["Physician Scientist-Programme"]}],"id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Stereotactic Body Radiotherapy (SBRT) is a standard treatment for inoperable primary and secondary lung tumors. In case of ultracentral tumor location, defined as tumor contact with vulnerable mediastinal structures such as the proximal bronchial tree (PBT) or esophagus, SBRT is associated with an increased risk for severe complications. Magnetic resonance (MR)-guided SBRT can mitigate this risk based on gated dose delivery and daily plan adaptation. The MAGELLAN trial aims to find the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung tumors (ULT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>MAGELLAN is a prospective phase I dose escalation trial. A maximum of 38 patients with primary and secondary ULT with a tumor size\u2009\u2264\u20095\u00a0cm will be enrolled. Ultracentral location is defined as an overlap of the planning target volume (PTV) with the PBT or esophagus. Patients are treated at a 0.35 Tesla MR-linac (MRIdian\u00ae Linac, ViewRay Inc.\n) employing a gating strategy and daily plan adaptation. Dose escalation starts at 10\u2009\u00d7\u20095.5\u00a0Gy (biologically effective dose BED<jats:sub>3\/10<\/jats:sub>: 155.83\u00a0Gy\/85.25\u00a0Gy), may proceed up to 10\u2009\u00d7\u20096.5\u00a0Gy (BED<jats:sub>3\/10<\/jats:sub>: 205.83\u00a0Gy\/107.25\u00a0Gy) and is guided by a customized time-to-event continual reassessment method (TITE CRM) with backup element, which alternately assigns patients to dose escalation and backup cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of the MAGELLAN trial will guide further research and clinical implementation of MR-guided SBRT as ablative treatment of ULT.\n Moreover, the combination of MR-guided radiotherapy with TITE-CRM including a backup element may serve as blueprint for future radiation dose escalation studies in critical locations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial Registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>Registered at ClinicalTrials.gov: NCT04925583 on 14th June 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02070-x","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T14:08:38Z","timestamp":1653487718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)"],"prefix":"10.1186","volume":"17","author":[{"given":"Sebastian","family":"Regnery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ristau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon David","family":"Sprengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Maria","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Buchele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Rippke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Katharina","family":"Renkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Welzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Alexander","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"issue":"2","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0360-3016(02)04504-2","volume":"56","author":"H Hof","year":"2003","unstructured":"Hof H, Herfarth KK, M\u00fcnter M, Hoess A, Motsch J, Wannenmacher M, et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2003;56(2):335\u201341. https:\/\/doi.org\/10.1016\/s0360-3016(02)04504-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2070_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","volume":"74","author":"M Guckenberger","year":"2009","unstructured":"Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47\u201354. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.06.1939.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2070_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.radonc.2020.01.010","volume":"145","author":"D Pasalic","year":"2020","unstructured":"Pasalic D, Lu Y, Betancourt-Cuellar SL, Taku N, Mesko SM, Bagley AF, et al. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2020;145:178\u201385. https:\/\/doi.org\/10.1016\/j.radonc.2020.01.010.","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"issue":"2","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","volume":"6","author":"JM Haseltine","year":"2016","unstructured":"Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2016;6(2):e27-33. https:\/\/doi.org\/10.1016\/j.prro.2015.09.012.","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"2070_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","volume":"11","author":"H Tekatli","year":"2016","unstructured":"Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer. 2016;11(7):1081\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.008.","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"2070_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.019","author":"K Lindberg","year":"2021","unstructured":"Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersall P, et al. The HILUS-Trial-a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer. 2021. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.019.","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"2070_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.11.003","author":"S Regnery","year":"2020","unstructured":"Regnery S, Eichkorn T, Weykamp F, Held T, Weusthof K, Dinges LA, et al. Safety and efficacy of stereotactic body radiotherapy in ultracentral lung tumors using a risk-optimized fractionation scheme. Clin Lung Cancer. 2020. https:\/\/doi.org\/10.1016\/j.cllc.2020.11.003.","journal-title":"Clin Lung Cancer"},{"key":"2070_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757031","volume":"11","author":"S Regnery","year":"2021","unstructured":"Regnery S, Buchele C, Weykamp F, Pohl M, Hoegen P, Eichkorn T, et al. Adaptive MR-guided stereotactic radiotherapy is beneficial for ablative treatment of lung tumors in high-risk locations. Front Oncol. 2021;11: 757031. https:\/\/doi.org\/10.3389\/fonc.2021.757031.","journal-title":"Front Oncol"},{"issue":"3","key":"2070_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.radonc.2009.08.040","volume":"93","author":"H Hof","year":"2009","unstructured":"Hof H, Rhein B, Haering P, Kopp-Schneider A, Debus J, Herfarth K. 4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2009;93(3):419\u201323. https:\/\/doi.org\/10.1016\/j.radonc.2009.08.040.","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"2070_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.radonc.2019.10.013","volume":"144","author":"T Finazzi","year":"2020","unstructured":"Finazzi T, Palacios MA, Haasbeek CJA, Admiraal MA, Spoelstra FOB, Bruynzeel AME, et al. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2020;144:46\u201352. https:\/\/doi.org\/10.1016\/j.radonc.2019.10.013.","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"issue":"15","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/jco.18.00622","volume":"37","author":"A Bezjak","year":"2019","unstructured":"Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37(15):1316\u201325. https:\/\/doi.org\/10.1200\/jco.18.00622.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"27","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1200\/jco.2005.04.3844","volume":"24","author":"D Normolle","year":"2006","unstructured":"Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(27):4426\u201333. https:\/\/doi.org\/10.1200\/jco.2005.04.3844.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2070_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106605","volume":"111","author":"HM Dehbi","year":"2021","unstructured":"Dehbi HM, O\u2019Quigley J, Iasonos A. Controlled backfill in oncology dose-finding trials. Contemp Clin Trials. 2021;111: 106605. https:\/\/doi.org\/10.1016\/j.cct.2021.106605.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2070_CR14","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","volume":"19","author":"M Giuliani","year":"2018","unstructured":"Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glick D, et al. SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer\u2014a safety and efficacy trial. Clin Lung Cancer. 2018;19(4):e529\u201332. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.001.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijrobp.2019.08.059","volume":"106","author":"M Duijm","year":"2020","unstructured":"Duijm M, van der Voort van Zyp NC, van de Vaart P, Oomen-deHoop E, Mast ME, Hoogeman MS, et al. Predicting high-grade esophagus toxicity after treating central lung tumors with stereotactic radiation therapy using a normal tissue complication probability model. Int J Radiat Oncol Biol Phys. 2020;106(1):73\u201381. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2070_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.01.009","author":"BV Manyam","year":"2020","unstructured":"Manyam BV, Verdecchia K, Videtic GMM, Zhuang T, Woody NM, Wei W, et al. Validation of RTOG 0813 proximal bronchial tree constraints for pulmonary toxicity with stereotactic body radiation therapy for central non-small cell lung cancer. Int J Radiat Oncol*Biol*Phys. 2020. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.009.","journal-title":"Int J Radiat Oncol*Biol*Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02070-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T14:10:16Z","timestamp":1653487816000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02070-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study will be conducted according to the declaration of Helsinki and was approved by the local ethics board (Ethikkommission der Medizinischen Fakult\u00e4t Heidelberg; IRB number: S-208\/2021). Written informed consent must be obtained from each patient before trial inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. H.-R. and S. K. received speaker fees and travel reimbursement from ViewRay Inc. S.A.K. and J.D. received grants from View-Ray Inc. J. H.-R. received travel reimbursement from IntraOP Medical and Elekta Instrument AB as well as grants from IntraOP Medical and Varian Medical Systems outside the submitted work. S.A. received grants from Accuray International S\u00e0rl, Merck Serono GmbH and Novocure GmbH outside the submitted work. S.A. received consulting fees from Accuray International S\u00e0rl and honoraria for lectures\/presentations from Accuray International S\u00e0rl and MSD outside the submitted work. S.A. received travel reimbursements from AstraZeneca outside the submitted work. S.A. participated on advisory boards for Sanofi Genzyme outside the submitted work. S.A.K. received honoraria from IBA dosimetry outside the submitted work. J.D. received grants from CRI\u2014The Clinical Research Institute GmbH, Accuray Incorporated, Accuray International S\u00e0rl, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Merck Serono GmbH, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A., IntraOP Medical and Varian Medical Systems outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}